Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 258

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 258
---
 for fibrinogen from     
 2018 to 2020 are to be paid by the Company pursuant to a Framework Supply Agreement dated March 8, 2016, or Framework Supply Agreement, 
 by and between the Company and CSL, whereby CSL agreed to supply the Company with fibrinogen. On January 14, 2020, the Company received 
 a termination letter, or CSL Termination Letter. In the CSL Termination Letter, CSL demanded a total amount of $820, claiming it        
 was owed the minimum purchase commitment amounts under the Framework Supply Agreement not paid by the Company in 2018 and 2019. In      
 a subsequent correspondence, CSL additionally demanded interest and damages for lost profit, with an aggregate demand amount of $1,476. 
 The Company has disputed CSL’s payment demand and contends that CSL’s demands are baseless under the Framework Supply                   
 Agreement, as the minimum purchase commitment under the Framework Supply Agreement is conditional upon first obtaining approval of      
 the FDA and the European Medicines Evaluation Agency, or EMEA, and other quality and clinical milestones, none of which has occurred.   
 Notwithstanding, CSL claimed to have obtained a valid German court order in its favor and to endeavor to seek for its enforcement       
 in Israel. Company’s position is that CSL’s claim for the payment of the said unshipped minimum purchase commitments lacks              
 any ground under the terms of the Framework Supply Agreement and moreover, that the Company was never served with German judicial       
 documents (e.g., statement of claim) of CSL with translations in Hebrew, English or Arabic, as required under the applicable German     
 and international rules of proceeding. Consequently, based on advice of a German legal counsel, the Company is in the opinion that      
 the legal proceeding initiated by CSL suffered a fundamental and material procedural error and that no enforceable German judgement     
 could derive thereto. In 2024, the Company has initiated a proceeding in Germany to annul said German court’s purported ruling.         |

From time to time, the Company has been
and may be in the future subject to other legal proceedings, claims, investigations, and government inquiries (collectively, “Legal
Proceedings”) in the ordinary course of business. There are no currently pending legal proceedings that the Company believes will
have a material adverse impact on the business or financial statements.

<div align='center'>F-14</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS